AbstractWe retrospectively investigated the outcome of 30 newly diagnosed patients with mantle cell lymphoma treated with high-dose therapy and autologous stem cell transplantation in first response. With a median follow-up of 55 months, the 5-year overall-survival is 62%, the 5-year progression-free-survival is 40% and no secondary malignancy has occurred.
Figures & Tables
Vol. 90 No. 11 (2005): November, 2005 : Comparative Studies
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com